Zimmer Biomet Holdings with ticker code (ZBH) now have 22 analysts in total covering the stock. The consensus rating is ‘Hold’. The target price ranges between 145 and 100 with a mean TP of 123.91. Now with the previous closing price of 105.42 this indicates there is a potential upside of 17.5%. The day 50 moving average is 109.4 while the 200 day moving average is 114.88. The company has a market capitalisation of $22,003m. Company Website: https://www.zimmerbiomet.com
The potential market cap would be $25,862m based on the market concensus.
Zimmer Biomet Holdings, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings and changed its name to Zimmer Biomet Holdings in June 2015. Zimmer Biomet Holdings was founded in 1927 and is headquartered in Warsaw, Indiana.
